Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Genomics BioSci & Tech Co., Ltd. (4195:TWSE), powered by AI.
Genomics BioSci & Tech Co., Ltd. is currently trading at $15.70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Genomics BioSci & Tech Co., Ltd. on Alpha Lenz.
View Genomics BioSci & Tech Co., Ltd.'s valuation metrics on Alpha Lenz.
“Genomics BioSci & Tech Co., Ltd.'s ROE is -7.4%. Explore profitability and growth together.”
Ask for details →Genomics BioSci & Tech Co., Ltd. is a biotechnology company specializing in the manufacture, research, and development of genomic solutions and biotechnological services. Established in 2001 and headquartered in New Taipei City, Taiwan, the company leverages advanced DNA sequencing technologies, including first, second, and third-generation sequencing platforms, to provide comprehensive laboratory and bioinformatics services. Its offerings span DNA and gene sequencing, oligonucleotide and peptide synthesis, genomic and proteomic analysis, as well as antibody preparation and mutation detection. Genomics BioSci & Tech Co., Ltd. also delivers contract development and manufacturing services (CDMO), catering to the pharmaceutical, vaccine adjuvant, cellular, and gene therapy industries. A significant player in Taiwan's health technology sector, the company serves research institutions, healthcare providers, and commercial clients, supporting scientific innovation and the advancement of precision medicine through a robust infrastructure and experienced professional teams. Genomics BioSci & Tech Co., Ltd. holds international certifications and emphasizes quality assurance across its product and service portfolio.
“Genomics BioSci & Tech Co., Ltd.'s ROE is -7.4%. Explore profitability and growth together.”
Ask for details →Genomics BioSci & Tech Co., Ltd. (ticker: 4195) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 15.7 with a P/E ratio of -x and P/B of -x.
ROE is -7.45% and operating margin is -10.53%. Annual revenue is $708M.